Clinical trial
A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
NCT00213135 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
- Lead sponsor
- EMD Serono
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2005
- Completion date
- November 30, 2008
- Enrollment
- 1,326 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.